NEW YORK (GenomeWeb) – Veracyte announced yesterday that its Afirma Thyroid FNA analysis test, which uses a set of gene expression signatures to differentiate benign thyroid nodules from cancerous ones, will become an Aetna in-network test beginning July 1.

Afirma employs a 142-gene signature to identify benign thyroid nodules in patients whose fine needle aspiration biopsies are deemed indeterminate following traditional cytopathology review and thus face a potentially unnecessary diagnostic surgery.

The test first received a positive coverage decision by Aetna in mid-2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.